medigraphic.com
ISSN 0001-0944 (Impreso)
Órgano Oficial de la Asociación Dental Mexicana

2009, Número 1

<< Anterior Siguiente >>

Rev ADM 2009; 66 (1)


Osteonecrosis de los maxilares asociada a bifosfonatos en pacientes con cáncer

Toranzo FJM, Flores VCE, Amarillas EED

Idioma: Español
Referencias bibliográficas: 25
Paginas: 46-49
Archivo PDF: 173.38 Kb.


RESUMEN

Se presenta un estudio epidemiológico sobre la frecuencia de osteonecrosis de los maxilares asociada a la utilización de bifosfonatos en pacientes con cáncer. La información fue obtenida de la base de datos del Hospital Central “Dr. Ignacio Morones Prieto” de San Luis Potosí en el periodo comprendido de 1998 a 2006. Durante este periodo se administraron bifosfonatos a 50 pacientes con diagnósticos de cáncer de mama, próstata y mieloma múltiple, y sólo 7 (14%) de ellos presentaron osteonecrosis mandibular. El Ácido Zoledrónico fue el causante más frecuente de esta patología con 4 (57%) casos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brooks JK, Gilson AJ, Sindier AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with use of risedronato: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 780-786.

  2. Cizmeci SF, Saracoglu TU, Durmus A, Bagis B. severe osteomielitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007; 65: 562-565.

  3. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 186-193.

  4. Hellstein JE, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): It this phossy jaw of the 21 S` century? J Oral Maxillofac Surg 2005; 63: 682-689.

  5. Wang J, Goodger NM, Progrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-1117.

  6. Assael L. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 2004; 62: 139-143.

  7. Estilo CI, Poznack VC, Williams T. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. Proc Am Soc Clin Oncol 2004; 22: 750-755.

  8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws. A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115 1117.

  9. Ruggiero Sí—, Mebrota B, Rosenberg TJ, Engroff Sí—. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-533.

  10. American Association of Oral and Maxillofacial Surgeons position paper on bis phosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65. 369-376.

  11. Zavras Al, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medica) claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006; 64: 917-923.

  12. American Dental Association council on scientific affairs: Dental management of patient receiving oral bisphosphonate therapy. JADA 2006; 137: 1144-1150.

  13. Starck WJ, Epker BN. Failure of osteointegrated dental implants after disphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 1995; 10: 74-78.

  14. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.

  15. Martins CM, Saraceni IC, Henrique KD, Rocha AS, Feher O, Oliveira dM, Zardetto C. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologus platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007; 65: 349-355.

  16. Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 1650-1654.

  17. Woo SB, Hellstein JW, Kalmar J. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.

  18. Wang PE, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328-1331.

  19. Bianchi SD, Scoletta M, Bozzalla CF, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 249-258.

  20. Chiandussi S, Biasotto M. Dore F, Cava¡¡ F, Cova MA, Lenerda RD. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006; 35: 236-243.

  21. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchez JM. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-124.

  22. Hoff AO, Toth BB, Altundag K. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006; 24: 8S.

  23. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosponate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.

  24. Freiberger JJ, Padilla BR, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Piantadosi CA. Hyperbaric oxygen treatment and bisphosphonateinduced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007; 65: 1321-1327.

  25. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1-34)]. J Oral Maxillofac Surg 2007; 65: 573-580.




2020     |     www.medigraphic.com